People with macular degeneration and other forms of central vision loss can see details like text and faces with this device.

Myopia, or nearsightedness, is a common eye condition. More than 40% of Americans can't see clearly at a distance because their eye is longer than normal. Usually myopia doesn't cause any problems ...

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Clinical investigations have demonstrated variation in both the peak optical density and the spatial distribution of macular pigment. To confirm these impressions histologically, the present study ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. The stock dropped 71% to 45 cents a share in after-hours ...

Ophthalmologist and retinal surgeon Dimitra Skondra, MD, Ph.D., knows that developing any new treatment can be fraught with false hopes and unexpected setbacks. She is cautiously optimistic, however, ...

The macula is the center part of your retina. It gives you your central vision, what you see right in front of you. When the macula is damaged, you can still see around the edges of your vision, ...

In a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found that levels of a specific protein appear to help accurately predict whether people with the wet form of ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...